Recordati Industria Chimica e Farmaceutica Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Rob Koremans
Chief executive officer
€2.2m
Total compensation
| CEO salary percentage | 27.4% |
| CEO tenure | 2.4yrs |
| CEO ownership | n/a |
| Management average tenure | 3.5yrs |
| Board average tenure | 4.7yrs |
Recent management updates
Recent updates
Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25
Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Jan 09Risks To Shareholder Returns Are Elevated At These Prices For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.57
Nov 12Is Recordati Industria Chimica e Farmaceutica (BIT:REC) Using Too Much Debt?
Sep 29Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 08Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 23Does This Valuation Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Imply Investors Are Overpaying?
Jun 05Recordati Industria Chimica e Farmaceutica's (BIT:REC) Conservative Accounting Might Explain Soft Earnings
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.60
Apr 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.60
Mar 19Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Mar 06A Look At The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Dec 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.55
Nov 11Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Intrinsic Value Is Potentially 42% Above Its Share Price
Sep 01These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Aug 07An Intrinsic Calculation For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Suggests It's 25% Undervalued
Jun 03Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 16Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 02Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.57
Apr 04Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.57
Mar 21These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Mar 06Calculating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has A Pretty Healthy Balance Sheet
Dec 05Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Sep 05A Look At The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jun 25Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 07Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts
May 10Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Shares Could Be 34% Above Their Intrinsic Value Estimate
Mar 11Here's What You Should Know About Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) 2.4% Dividend Yield
Feb 19Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | €389m |
| Sep 30 2023 | n/a | n/a | €375m |
| Jun 30 2023 | n/a | n/a | €389m |
| Mar 31 2023 | n/a | n/a | €340m |
| Dec 31 2022 | €2m | €590k | €312m |
| Sep 30 2022 | n/a | n/a | €331m |
| Jun 30 2022 | n/a | n/a | €330m |
| Mar 31 2022 | n/a | n/a | €393m |
| Dec 31 2021 | €154k | n/a | €386m |
Compensation vs Market: Rob's total compensation ($USD2.31M) is below average for companies of similar size in the Italian market ($USD3.96M).
Compensation vs Earnings: Rob's compensation has increased by more than 20% in the past year.
CEO
Rob Koremans (61 yo)
2.4yrs
Tenure
€2,154,000
Compensation
Dr. Robert Koremans, also known as Rob, M.D. serves as Chief Executive Officer and Director of Recordati Industria Chimica e Farmaceutica S.p.A. since December 1, 2021. Dr. Koremans served as Chief Executi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.4yrs | €2.15m | no data | |
| Group CFO & Executive Director | 4.5yrs | €1.11m | no data | |
| Executive Director | no data | no data | no data | |
| Executive Director | no data | no data | no data | |
| Executive Director | no data | no data | no data | |
| VP & Head of Investor Relations | less than a year | no data | no data | |
| Group Chief Legal Officer | 1.1yrs | no data | no data | |
| Group Communications Director | no data | no data | no data | |
| Executive VP of Corporate Development | 7.7yrs | no data | no data | |
| Group Chief People & Culture Officer | less than a year | no data | no data | |
| Executive Vice President of Group Industrial Operations | 9.1yrs | no data | no data | |
| Chief Medical Officer | 5.3yrs | no data | no data |
3.5yrs
Average Tenure
54yo
Average Age
Experienced Management: REC's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.4yrs | €2.15m | no data | |
| Group CFO & Executive Director | 2.3yrs | €1.11m | no data | |
| Executive Director | 5.4yrs | no data | no data | |
| Executive Director | 5.4yrs | no data | no data | |
| Executive Director | 4.1yrs | no data | no data | |
| Non-Executive Chairman | 26.1yrs | €352.00k | no data | |
| Independent Non-Executive Director | 4.1yrs | €77.00k | no data | |
| Lead Independent Director | 10.1yrs | €98.00k | no data | |
| Independent Director | 2.3yrs | €61.00k | no data | |
| Chairman of Statutory Auditor Board | 7.1yrs | no data | no data | |
| Independent Non-Executive Director | 5.3yrs | €82.00k | no data | |
| Non-Executive Vice Chairman | 4.1yrs | €60.00k | no data |
4.7yrs
Average Tenure
53.5yo
Average Age
Experienced Board: REC's board of directors are considered experienced (4.7 years average tenure).